GGrantIndex
← Leaderboards

Lawrence D Kaplan

University Of California San Francisco

$3,830,195
Attributed
$3,830,195
Total exposure
6
Grants
2
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $584.3K · FY200514
$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14

Funding mix

By agency

NIH$3,830,195 · 6

By mechanism

U01$3,488,349 · 3
K12$318,948 · 1
M01$22,898 · 2

Top collaborators

No co-investigators on record.

Most similar at University Of California San Francisco

Same institution · by research overlap

Others in their field

Top investigators on “Neoplasm /Cancer Chemotherapy

Research focus

Neoplasm /Cancer ChemotherapyClinical ResearchPharmacokineticsHuman Therapy EvaluationLymphomaDrug Screening /EvaluationKaposi'S SarcomaHuman SubjectClinical TrialsHiv InfectionsHuman PapillomavirusAids Related Neoplasm /CancerAidsCancer CenterNeoplasmsNonhodgkin'S LymphomaBerryNeoplasm /Cancer VaccineMacrophageClinical Trial Phase IAnalogEnrollmentNeoplasm /Cancer TherapyResearch Personnel

Grant awards (23)

UCSF Core Site$166,391
U01 · FY2014 · CA · contact PI
UCSF Core Site$584,309
U01 · FY2013 · CA · contact PI
UCSF Core Site$541,546
U01 · FY2012 · CA · contact PI
UCSF Core Site$40,909
U01 · FY2012 · CA · contact PI
UCSF Core Site$538,004
U01 · FY2011 · CA · contact PI
UCSF Core Site$417,934
U01 · FY2010 · CA · contact PI
University of California - San Francisco$150,000
U01 · FY2006 · CA · contact PI
AIDS ASSOCIATED MALIGNANCIES CLINICAL TRIALS CONSORTIUM$113,917
U01 · FY2005 · CA
SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF CGC-11047 (SL-11047) IN REFRACTORY$15,900
M01 · FY2005 · RR
AIDS ASSOCIATED MALIGNANCIES CLINICAL TRIALS CONSORTIUM$82,829
U01 · FY2004 · CA
Safety, Tolerability, and Pharmacokinetics of SL-11047 in Refractory Lymphoma$6,998
M01 · FY2004 · RR
AIDS ASSOCIATED MALIGNANCIES CLINICAL TRIALS CONSORTIUM$252,735
U01 · FY2003 · CA
AIDS ASSOCIATED MALIGNANCIES CLINICAL TRIALS CONSORTIUM$249,154
U01 · FY2002 · CA
COL-3 IN PATIENTS WITH HIV RELATED KAPOSI'S SARCOMA$0
M01 · FY2002 · RR
COL-3 IN PATIENTS WITH HIV RELATED KAPOSI'S SARCOMA$0
M01 · FY2002 · RR
AIDS ASSOCIATED MALIGNANCIES CLINICAL TRIALS CONSORTIUM$199,000
U01 · FY2001 · CA
INSTITUTIONAL CLINICAL SCIENTIST DEVELOPMENT AWARD$125,806
K12 · FY2001 · CA
COL-3 IN PATIENTS WITH HIV RELATED KAPOSI'S SARCOMA$0
M01 · FY2001 · RR
INSTITUTIONAL CLINICAL SCIENTIST DEVELOPMENT AWARD$193,142
K12 · FY2000 · CA
AIDS ASSOCIATED MALIGNANCIES CLINICAL TRIALS CONSORTIUM$151,621
U01 · FY2000 · CA
COL-3 IN PATIENTS WITH HIV RELATED KAPOSI'S SARCOMA$0
M01 · FY2000 · RR
COL-3 IN PATIENTS WITH HIV RELATED KAPOSI'S SARCOMA$0
M01 · FY2000 · RR
COL-3 IN PATIENTS WITH HIV RELATED KAPOSI'S SARCOMA$0
M01 · FY2000 · RR